ライフサイエンスコーパス: cangrelor

1 eeding episodes were numerically higher with cangrelor.

2 tk, respectively, or by the P2Y12 antagonist cangrelor.

3 ch patients were being actively treated with cangrelor.

4 2-fold decrease in platelet reactivity with cangrelor.

5 platelet reactivity rates were reduced with cangrelor.

6 uding prasugrel, ticagrelor, and intravenous cangrelor.

7 e similar in both women and men treated with cangrelor (0.3% versus 0.2%, P=0.30 [women]; 0.1% versus

8 clopidogrel group (adjusted odds ratio with cangrelor, 0.78; 95% confidence interval [CI], 0.66 to 0

9 on (placebo, 1.63 [0.60-4.65] %LVmass versus cangrelor, 1.18 [0.53-3.37] %LVmass; P=0.46) between pla

10 9, 100 micromol/L) and especially P(2)Y(12) (Cangrelor, 10 micromol/L) blunted CXCL16-triggered plate

11 ze (placebo, 14.9% [7.3-22.6] %LVmass versus cangrelor, 16.3 [9.9-24.4] %LVmass; P=0.40) or the incid

12 y 48 hours identified by the CEC (207 [3.8%] cangrelor; 255 [4.7%] clopidogrel; odds ratio [OR] 0.80;

13 =0.40) or the incidence (placebo, 48% versus cangrelor, 47%; P=0.99) and extent of microvascular obst

14 t occurred in 185 of 2654 patients receiving cangrelor (7.0%) and in 210 of 2641 patients receiving p

15 MI by 48 hours reported by the SI (60 [1.1%] cangrelor; 83 [1.5%] clopidogrel; OR, 0.72; 95% CI, 0.52

16 h tirofiban, which yielded superior IPA over cangrelor (95.0+/-8.9 versus 34.1+/-22.5; P<0.001).

17 rivative (a specific P2X(1) antagonist), and cangrelor (a specific P2Y(12) antagonist) mitigated the

18 on Triage Strategy criteria) was higher with cangrelor, a difference that approached statistical sign

19 Cangrelor, a nonthienopyridine adenosine triphosphate an

20 Intravenous cangrelor, a rapid-acting, reversible adenosine diphosph

21 Cangrelor administered at the time of primary percutaneo

22 ee trials that assessed the effectiveness of cangrelor against either clopidogrel or placebo in PCI.

23 significantly lower in patients treated with cangrelor alone (0.7% vs 2.4%; OR, 0.29; 95% CI, 0.13-0.

24 were not significantly different between the cangrelor alone and clopidogrel-GPI groups (2.6% vs 3.3%

25 efined severe/life-threatening bleeding with cangrelor alone compared with clopidogrel-GPI (0.3% vs 0

26 analysis from the 3 phase 3 CHAMPION trials, cangrelor alone was associated with similar ischemic ris

27 ssigned to cangrelor but not receiving GPIs (cangrelor alone) and 1211 patients assigned to clopidogr

28 a inhibitors (eptifibatide or tirofiban) and cangrelor, an intravenous P2Y(12) inhibitor.

29 Thrombotic events are reduced with cangrelor, an intravenous P2Y(12) inhibitor.

30 Cangrelor, an intravenous, reversible P2Y12 antagonist,

31 event >1 year old, including 650 assigned to cangrelor and 620 assigned to clopidogrel.

32 P2Y12 and alphaIIbbeta3 receptor inhibitors cangrelor and abciximab, respectively, both in vitro--by

33 aracteristics were well balanced between the cangrelor and clopidogrel arms in subsets receiving and

34 0.6%) and 54 of 5,469 (1.0%) patients in the cangrelor and clopidogrel arms, respectively (odds ratio

35 11.8% (12 of 102) vs 10.4% (10 of 96) in the cangrelor and placebo groups, respectively (RR, 1.1 [95%

36 ups, ruling out a drug-drug interaction when cangrelor and ticagrelor are concomitantly administered.

37 of GPR17 by the marketed antiplatelet drugs cangrelor and ticagrelor, previously suggested to antago

38 el P2Y12 antagonists (prasugrel, ticagrelor, cangrelor, and elinogrel) that have advantages over clop

39 triethylammonium salt hydrate (2MeSAMP) and Cangrelor (AR-C69931MX) have been widely used to demonst

40 The administration of intravenous cangrelor at reperfusion achieves faster onset of platel

41 We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent

42 Cangrelor at the time of percutaneous coronary intervent

43 TER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicent

44 icipants included 10929 patients assigned to cangrelor but not receiving GPIs (cangrelor alone) and 1

45 ation showed a trend toward a reduction with cangrelor, but it was not significant (0.6% vs. 0.9%; od

46 linical Trial to Demonstrate the Efficacy of Cangrelor), CHAMPION PLATFORM (Cangrelor Versus Standard

47 gin of 9%, superiority of both tirofiban and cangrelor compared with chewed prasugrel, and superiorit

48 and there was no significant difference with cangrelor compared with clopidogrel (0.2% [n=10] versus

49 and there was no significant difference with cangrelor compared with clopidogrel (0.2% [n=10] versus

50 e primary composite endpoint were lower with cangrelor compared with clopidogrel in patients who did

51 ought to evaluate the efficacy and safety of cangrelor compared with clopidogrel in subgroups that di

52 Cangrelor compared with clopidogrel significantly reduce

53 ention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that

54 therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rat

55 ered to test 3 hypotheses (noninferiority of cangrelor compared with tirofiban using a noninferiority

56 large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic end poi

57 Compared with clopidogrel, cangrelor consistently reduced the primary outcome in bo

58 nduces food intake, whereas Gpr17 antagonist cangrelor curtails it.

59 3-3.37] %LVmass; P=0.46) between placebo and cangrelor despite a 2-fold decrease in platelet reactivi

60 The dose of cangrelor determined in 10 patients in the open-label st

61 Cangrelor did not increase the primary safety endpoint,

62 At 30 minutes, cangrelor did not satisfy noninferiority compared with t

63 rdioprotection, whereas the P2Y12 antagonist cangrelor does not.

64 The use of periprocedural cangrelor during PCI was not superior to placebo in redu

65 forskolin) of the cAMP pathway, 2MeSAMP and Cangrelor failed to inhibit Ca(2+) mobilization, Akt pho

66 roduction of an intravenous P2Y12 inhibitor (cangrelor) further adds to the multitude of modalities a

67 he primary safety end point was 0.16% in the cangrelor group and 0.11% in the clopidogrel group (odds

68 n the rate of blood transfusion (1.0% in the cangrelor group and 0.6% in the placebo group, P=0.13),

69 e primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (adjus

70 t, which occurred in 7.5% of patients in the cangrelor group and 7.1% of patients in the clopidogrel

71 sis developed in 0.8% of the patients in the cangrelor group and in 1.4% in the clopidogrel group (od

72 e primary efficacy end point was 4.3% in the cangrelor group versus 5.3% in the clopidogrel group (od

73 receiving placebo (8.0%) (odds ratio in the cangrelor group, 0.87; 95% confidence interval [CI], 0.7

74 In the cangrelor group, as compared with the placebo group, two

75 r bleeding on one scale was increased in the cangrelor group, from 3.5% to 5.5% (P<0.001), because of

76 stent thrombosis and death were lower in the cangrelor group, with no significant increase in the rat

77 greater proportion of patients treated with cangrelor had low levels of platelet reactivity througho

78 end point, stent thrombosis, were reduced by cangrelor in both regions.

79 imary efficacy and safety end point) favored cangrelor in both women (OR, 0.68; 95% CI, 0.50-0.92) an

80 chemic events and overall efficacy seen with cangrelor in CHAMPION PHOENIX occurred early and during

81 were low and not significantly increased by cangrelor in either region.

82 N) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in pat

83 this analysis, we evaluated the efficacy of cangrelor in the first 2 hours postrandomization with re

84 s GUSTO moderate/severe bleeding, the OR for cangrelor in those >/=75 years old was 0.75 (6.4% versus

85 bitors (GPIs) and a potent P2Y12 antagonist, cangrelor, in patients undergoing PCI.

86 0.4%), or in transfusion (0.7% vs 0.6%), but cangrelor increased GUSTO mild bleeding (16.8% vs 13.0%,

87 Cangrelor increased the odds of moderate bleeding in wom

88 evealed that neither 2MeSAMP nor ARC69931MX (cangrelor) increased cAMP through activation of A2a, IP,

89 lucidate the mechanisms by which 2MeSAMP and Cangrelor inhibit platelet activation and thrombosis.

90 e data together demonstrate that 2MeSAMP and Cangrelor inhibit platelet function through the P2Y(12)-

91 2MeSAMP and Cangrelor inhibited aggregation and ATP release of wild-

92 Importantly, while injection of Cangrelor inhibited thrombus formation in a FeCl(3)-indu

93 Cangrelor is a potent intravenous adenosine diphosphate

94 Cangrelor is a potent intravenous adenosine diphosphate-

95 Cangrelor is a potent, rapid-acting, reversible intraven

96 Periprocedural cangrelor is an effective and safe antiplatelet agent, i

97 primary percutaneous coronary intervention, cangrelor is an effective strategy to bridge the gap in

98 Cangrelor is an intravenous ADP receptor antagonist that

99 Cangrelor is an intravenous P2Y(12) inhibitor with promp

100 Cangrelor is an intravenous P2Y12 inhibitor approved to

101 Cangrelor is being evaluated in clinical trials of throm

102 rther study of intravenous ADP blockade with cangrelor may be warranted.

103 nfarction were randomly allocated (1:1:1) to cangrelor (n=40), tirofiban (n=40) (both administered as

104 2MeSAMP and Cangrelor neither raised intracellular cAMP concentratio

105 The effect of cangrelor on ischemic events and bleeding was analyzed i

106 r total MIs (n=134); however, the effects of cangrelor on MI remained significant (OR, 0.65; 95% CI,

107 ere seen in the evaluation of the effects of cangrelor on MIs with peak creatinine kinase-MB >/=10 ti

108 We explored the effects of cangrelor on myocardial infarction (MI) using different

109 total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPION PHOENIX trial (

110 rgoing percutaneous coronary intervention to cangrelor or clopidogrel.

111 ng rates, regardless of the randomization to cangrelor or clopidogrel.

112 ition) PHOENIX randomized 11 145 patients to cangrelor or clopidogrel.

113 urgent percutaneous coronary intervention to cangrelor or clopidogrel.

114 who were randomized to treatment with either cangrelor or matching placebo (bolus followed by 2-hour

115 dine awaiting CABG surgery to receive either cangrelor or placebo after an initial open-label, dose-f

116 n treated with clopidogrel to receive either cangrelor or placebo at the time of PCI, followed by 600

117 were stopped and patients were administered cangrelor or placebo for at least 48 hours, which was di

118 Patients were randomized to receive either cangrelor or placebo initiated before the primary percut

119 Cangrelor or tirofiban were both superior to chewed pras

120 d therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300

121 linical Trial to Demonstrate the Efficacy of Cangrelor [PCI]: NCT00305162; Cangrelor Versus Standard

122 ministered as crushed tablets at the time of cangrelor/placebo bolus administration.

123 After discontinuation of cangrelor/placebo infusion, there were no differences in

124 Cangrelor provided inferior IPA compared with tirofiban;

125 recent study reported that both 2MeSAMP and Cangrelor raise intra-platelet cAMP levels and inhibit p

126 pared with control (clopidogrel or placebo), cangrelor reduced PCI periprocedural thrombotic complica

127 In randomized trials, cangrelor reduced periprocedural ischemic events related

128 Cangrelor reduced rates of the primary composite end poi

129 Treatment with cangrelor reduced the composite end point of death, MI (

130 Treatment with cangrelor reduced the incidence of MI at 48 hours (3.8%

131 In CHAMPION PHOENIX, cangrelor reduced the odds of major adverse cardiovascul

132 Cangrelor reduced the odds of stent thrombosis by 61% in

133 Cangrelor reduced the odds of the primary end point by 3

134 Cangrelor reduced the odds of the primary outcome by 19%

135 Cangrelor reduced the odds of the secondary triple compo

136 In the CHAMPION PHOENIX trial, cangrelor reduced the primary composite end point of dea

137 eding, were similar, as were the benefits of cangrelor, regardless of the timing.

138 Cangrelor resulted in directionally consistent effects o

139 Cangrelor's efficacy in reducing ischemic complications

140 In the first 2 hours after randomization, cangrelor significantly decreased the primary composite

141 Compared with clopidogrel, cangrelor significantly reduced MIs identified by the CE

142 e Percutaneous Coronary Intervention) trial, cangrelor significantly reduced periprocedural and 30-da

143 Cangrelor significantly reduced the rate of ischemic eve

144 intravenous adenosine diphosphate antagonist cangrelor substantially reduced IPST, contributing to it

145 occurred significantly more frequently with cangrelor than with clopidogrel (1.2% vs. 0.3%).

146 We aimed to investigate the effects of cangrelor, tirofiban, and prasugrel, administered as che

147 (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Sub

148 CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Sub

149 d CHAMPION PHOENIX (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Sub

150 CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Wh

151 RM]: NCT00385138; A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Wh

152 CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Wh

153 drug interactions during the transition from cangrelor to oral P2Y(12) inhibitors.

154 te, there are limited data on the effects of cangrelor used in combination with ticagrelor in patient

155 rence in GUSTO moderate/severe bleeding with cangrelor versus clopidogrel (1.1% versus 1.0%; OR, 1.07

156 Platelet Inhibition) who were randomized to cangrelor versus clopidogrel during percutaneous coronar

157 severe bleeding among patients who received cangrelor versus placebo who were obese (0.6% versus 0.6

158 efficacy end point in patients who received cangrelor versus placebo who were obese (3.9% versus 4.7

159 Patients from the 3 CHAMPION trials (Cangrelor Versus Standard Therapy to Achieve Optimal Man

160 he Efficacy of Cangrelor [PCI]: NCT00305162; Cangrelor Versus Standard Therapy to Achieve Optimal Man

161 d, patient-level analysis of the 3 CHAMPION (Cangrelor versus Standard Therapy to Achieve Optimal Man

162 METHODS AND CHAMPION (cangrelor versus standard therapy to achieve optimal man

163 e Efficacy of Cangrelor), CHAMPION PLATFORM (Cangrelor Versus Standard Therapy to Achieve Optimal Man

164 r clopidogrel in the CHAMPION PHOENIX trial (Cangrelor versus Standard Therapy to Achieve Optimal Man

165 The Cangrelor Versus Standard Therapy to Achieve Optimal Man

166 The Cangrelor versus Standard Therapy to Achieve Optimal Man

167 odds of the primary outcome by 19% (3.8% for cangrelor vs 4.7% for control; odds ratio [OR] 0.81, 95%

168 pooled patient-level data from the 3 phase 3 Cangrelor vs Standard Therapy to Achieve Optimal Managem

169 Compared with placebo, cangrelor was associated with reduced P2Y(12) reaction u

170 , double-blind, double-dummy trials in which cangrelor was compared with clopidogrel during percutane

171 Likewise, cangrelor was not superior at 30 days.

172 At 48 hours, cangrelor was not superior to clopidogrel with respect t

173 Cangrelor, when administered intravenously 30 minutes be

174 Cangrelor, when compared with clopidogrel, provides simi

175 a large-scale international trial comparing cangrelor with 600 mg of oral clopidogrel administered b

176 tion) double-blind randomized trial compared cangrelor with clopidogrel loading dose at the time of P

177 ION-PLATFORM, and CHAMPION-PHOENIX) compared cangrelor with control (clopidogrel or placebo) for prev

178 The benefit from cangrelor with respect to the primary end point was cons

179 as a crushed formulation concomitantly with cangrelor without any apparent drug-drug interaction.

180 t P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/I